Q1 Earnings Forecast for RLAY Issued By Leerink Partnrs

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Relay Therapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the company will post earnings of ($0.63) per share for the quarter. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($2.55) per share.

A number of other brokerages have also recently weighed in on RLAY. Leerink Partners reduced their price target on Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Wednesday, December 4th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Relay Therapeutics in a research report on Tuesday, January 14th. Finally, JMP Securities reiterated a “market outperform” rating and set a $21.00 price target on shares of Relay Therapeutics in a report on Thursday, December 12th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.50.

Relay Therapeutics Stock Down 5.8 %

RLAY stock opened at $4.51 on Friday. Relay Therapeutics has a 1 year low of $3.50 and a 1 year high of $11.16. The company has a fifty day simple moving average of $4.51 and a 200 day simple moving average of $5.98.

Relay Therapeutics (NASDAQ:RLAY) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.14. The firm’s revenue was down 100.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.54) earnings per share.

Institutional Investors Weigh In On Relay Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bellevue Group AG boosted its position in shares of Relay Therapeutics by 15.7% during the 3rd quarter. Bellevue Group AG now owns 7,377,184 shares of the company’s stock valued at $52,230,000 after acquiring an additional 1,000,069 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Relay Therapeutics by 39.2% during the third quarter. JPMorgan Chase & Co. now owns 5,517,516 shares of the company’s stock valued at $39,064,000 after purchasing an additional 1,554,115 shares in the last quarter. State Street Corp grew its stake in shares of Relay Therapeutics by 1.2% in the 3rd quarter. State Street Corp now owns 4,300,216 shares of the company’s stock valued at $30,446,000 after purchasing an additional 51,810 shares during the period. Braidwell LP raised its holdings in shares of Relay Therapeutics by 16.4% in the 3rd quarter. Braidwell LP now owns 3,499,427 shares of the company’s stock worth $24,776,000 after buying an additional 492,628 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Relay Therapeutics by 15.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,732,270 shares of the company’s stock worth $19,348,000 after buying an additional 367,473 shares during the period. Institutional investors own 96.98% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Thomas Catinazzo sold 36,036 shares of Relay Therapeutics stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $4.63, for a total transaction of $166,846.68. Following the sale, the chief financial officer now directly owns 263,190 shares of the company’s stock, valued at $1,218,569.70. This trade represents a 12.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sanjiv Patel sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $5.00, for a total value of $500,000.00. Following the completion of the transaction, the chief executive officer now directly owns 574,548 shares of the company’s stock, valued at approximately $2,872,740. This trade represents a 14.82 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 354,646 shares of company stock worth $1,672,757 in the last ninety days. Insiders own 4.32% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.